News

The agreement will allow the company to assess its modified recombinant human albumin (rAlbumin) Veltis technology, to evaluate the dosing and performance of a novel subunit antigen vaccine

The company is currently carrying out in-vitro testing on these candidates using a robust screening process developed during testing of more advanced products that incorporate the DETERx technology

The company has partnered with Andrus for the distribution of Binosto in Russia, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine and Uzbekistan. Through another partnership,

The collaboration target and lead inhibitors were discovered through Array’s Kinase-Directed Phenotypic Screening Platform, which relies on the company’s deep experience in kinase inhibitor chemistry and phenotypic screening

Natesto, formerly CompleoTRT, is self-administered via a nasal applicator thereby reducing the risk of secondary exposure to testosterone of women or children. Clinical Research of South Florida (CRSA)

The company also received a second patent for ZORVOLEX (diclofenac) capsules covering its manufacturing method. ZORVOLEX and TIVORBEX were approved in October 2013 and February 2014, respectively, by

Euprotec is a recognised leader in anti-infective drug discovery services. With a comprehensive portfolio of assays and disease models, underpinned by internationally recognised expertise, the company supports each

These studies are the important first step in determining the safety and tolerability of new drugs. They test how drugs are absorbed into the body, and the amount

Fibrocell’s clinical program for RDEB will utilize PCT’s manufacturing expertise and resources to implement the production process for transfer and clinical manufacturing of genetically-modified cell therapies. The manufacturing